Document Detail

Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial.
MedLine Citation:
PMID:  22319066     Owner:  NLM     Status:  Publisher    
BACKGROUND: Clopidogrel is an inactive prodrug; it is converted to its active metabolite through the cytochrome P450 (CYP3A4) pathway, which also metabolizes calcium channel blockers (CCBs). Several studies have reported that CCBs reduce the ability of clopidogrel to inhibit platelet aggregability; one suggested that CCBs reduce the efficacy of clopidogrel. METHODS AND RESULTS: We performed a post hoc analysis of the Clopidogrel for the Reduction of Events During Observation (CREDO) study to compare the treatment effect of clopidogrel in patients on CCBs versus not on CCBs. In CREDO, 2116 patients were randomly assigned to pretreatment with 300 mg clopidogrel 3-24 hours before a planned percutaneous coronary intervention followed by 1 year of 75 mg/d clopidogrel, versus 75 mg clopidogrel at the time of the procedure and continued for 28 days only. The primary end points were a combined end point of death, myocardial infarction, and stroke at 28 days and 1 year. Among the 580 patients (27%) on CCBs at enrollment, at 28 days, the combined end point was reached in 17 patients (6%) on clopidogrel versus 28 (9%) on placebo (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.39-1.29). At 1 year, the combined end point was reached in 27 patients (10%) on clopidogrel versus 46 (15%) on placebo (HR, 0.68; 95% CI, 0.42-1.09). The treatment effect of clopidogrel was similar in patients not on CCBs at 1 year (HR, 0.78; 95% CI, 0.56-1.09). After adjustment for differences between patients on and not on CCB, there was still no evidence of an interaction between clopidogrel treatment and CCB (HR for patients not on CCBs, 0.87; 95% CI, 0.62-1.23; HR for patients on CCBs, 0.74; 95% CI, 0.45-1.21). CONCLUSIONS: In CREDO, there was no evidence that CCBs decrease the efficacy of clopidogrel.
Christopher W Good; Steven R Steinhubl; Danielle M Brennan; A Michael Lincoff; Eric J Topol; Peter B Berger
Related Documents :
22292486 - Atazanavir: in pediatric patients with hiv-1 infection.
22309786 - Long-term outcomes of percutaneous nephrolithotomy in patients with chronic kidney dise...
19542256 - Prospective evaluation of right ventricular function and functional status 6 months aft...
22668876 - Long-term follow-up of hepatitis b e antigen-negative patients treated with peginterfer...
15232596 - Long-term results of cataract extraction with intraocular lens implantation in patients...
10776876 - Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an in...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-7
Journal Detail:
Title:  Circulation. Cardiovascular interventions     Volume:  -     ISSN:  1941-7632     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101499602     Medline TA:  Circ Cardiovasc Interv     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Geisinger Clinic, Danville, PA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Percutaneous femoral arteriovenous shunt creation for advanced chronic obstructive pulmonary disease...
Next Document:  Long-Term Clinical Outcome After Fractional Flow Reserve-Guided Percutaneous Coronary Revascularizat...